463 related articles for article (PubMed ID: 21791194)
1. Plerixafor added to chemotherapy plus G-CSF is safe and allows adequate PBSC collection in predicted poor mobilizer patients with multiple myeloma or lymphoma.
Attolico I; Pavone V; Ostuni A; Rossini B; Musso M; Crescimanno A; Martino M; Iacopino P; Milone G; Tedeschi P; Coluzzi S; Nuccorini R; Pascale S; Di Nardo E; Olivieri A
Biol Blood Marrow Transplant; 2012 Feb; 18(2):241-9. PubMed ID: 21791194
[TBL] [Abstract][Full Text] [Related]
2. The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF.
D'Addio A; Curti A; Worel N; Douglas K; Motta MR; Rizzi S; Dan E; Taioli S; Giudice V; Agis H; Kopetzky G; Soutar R; Casadei B; Baccarani M; Lemoli RM
Bone Marrow Transplant; 2011 Mar; 46(3):356-63. PubMed ID: 20577218
[TBL] [Abstract][Full Text] [Related]
3. Plerixafor and G-CSF for PBSC mobilization in patients with lymphoma who failed previous attempts with G-CSF and chemotherapy: a REL (Rete Ematologica Lombarda) experience.
Arcaini L; Laszlo D; Rizzi S; Balzarotti M; Antoniazzi F; Zilioli VR; Guggiari E; Farina L; Todisco E; Bonfichi M; Alamos SM; Rossi G; Martinelli G; Morra E
Leuk Res; 2011 Jun; 35(6):712-4. PubMed ID: 21276613
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics.
Li J; Hamilton E; Vaughn L; Graiser M; Renfroe H; Lechowicz MJ; Langston A; Prichard JM; Anderson D; Gleason C; Lonial S; Flowers CR; Kaufman JL; Waller EK
Transfusion; 2011 Oct; 51(10):2175-82. PubMed ID: 21492180
[TBL] [Abstract][Full Text] [Related]
5. Plerixafor and G-CSF for autologous stem cell mobilization in patients with NHL, Hodgkin's lymphoma and multiple myeloma: results from the expanded access program.
Shaughnessy P; Uberti J; Devine S; Maziarz RT; Vose J; Micallef I; Jacobsen E; McCarty J; Stiff P; Artz A; Ball ED; Berryman R; Dugan M; Joyce R; Hsu FJ; Johns D; McSweeney P
Bone Marrow Transplant; 2013 Jun; 48(6):777-81. PubMed ID: 23178544
[TBL] [Abstract][Full Text] [Related]
6. Plerixafor in combination with granulocyte-colony-stimulating factor after chemotherapy increases mobilization efficiency in patients with lymphoma or myeloma: results of a Phase II clinical trial.
Jagirdar N; Harvey RD; Nooka A; Flowers C; Kaufman J; Lonial S; Lechowicz MJ; Langston A; Lipscomb C; Gaylor C; Waller EK
Transfusion; 2015 Oct; 55(10):2351-7. PubMed ID: 26331348
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma.
Cashen A; Lopez S; Gao F; Calandra G; MacFarland R; Badel K; DiPersio J
Biol Blood Marrow Transplant; 2008 Nov; 14(11):1253-61. PubMed ID: 18940680
[TBL] [Abstract][Full Text] [Related]
8. Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma.
Steinberg M; Silva M
Clin Ther; 2010 May; 32(5):821-43. PubMed ID: 20685493
[TBL] [Abstract][Full Text] [Related]
9. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.
Nademanee AP; DiPersio JF; Maziarz RT; Stadtmauer EA; Micallef IN; Stiff PJ; Hsu FJ; Bridger G; Bolwell BJ
Biol Blood Marrow Transplant; 2012 Oct; 18(10):1564-72. PubMed ID: 22683613
[TBL] [Abstract][Full Text] [Related]
10. Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide.
Malard F; Kröger N; Gabriel IH; Hübel K; Apperley JF; Basak GW; Douglas KW; Geraldes C; Jaksic O; Koristek Z; Lanza F; Lemoli R; Mikala G; Selleslag D; Worel N; Mohty M; Duarte RF
Biol Blood Marrow Transplant; 2012 Feb; 18(2):314-7. PubMed ID: 22001752
[TBL] [Abstract][Full Text] [Related]
11. Plerixafor use in patients with previous mobilization failure: A multicenter experience.
Tekgündüz E; Altuntaş F; Sıvgın S; Akı SZ; Dönmez A; Topçuoğlu P; Yıldırım R; Baysal NA; Ayyıldız E; Yüksel MK; Sarı I; Tombuloğlu M; Unal A; Ilhan O
Transfus Apher Sci; 2012 Aug; 47(1):77-80. PubMed ID: 22609192
[TBL] [Abstract][Full Text] [Related]
12. Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data.
Duarte RF; Shaw BE; Marín P; Kottaridis P; Ortiz M; Morante C; Delgado J; Gayoso J; Goterriz R; Martínez-Chamorro C; Mateos-Mazón JJ; Ramírez C; de la Rubia J; Achtereekte H; Gandhi PJ; Douglas KW; Russell NH
Bone Marrow Transplant; 2011 Jan; 46(1):52-8. PubMed ID: 20305700
[TBL] [Abstract][Full Text] [Related]
13. Phase I/II Study of Intravenous Plerixafor Added to a Mobilization Regimen of Granulocyte Colony-Stimulating Factor in Lymphoma Patients Undergoing Autologous Stem Cell Collection.
Cashen AF; Rettig M; Gao F; Smith A; Abboud C; Stockerl-Goldstein K; Vij R; Uy G; Westervelt P; DiPersio J
Biol Blood Marrow Transplant; 2017 Aug; 23(8):1282-1289. PubMed ID: 28476490
[TBL] [Abstract][Full Text] [Related]
14. Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program.
Worel N; Rosskopf K; Neumeister P; Kasparu H; Nachbaur D; Russ G; Namberger K; Witt V; Schloegl E; Zojer N; Linkesch W; Kalhs P; Greinix HT
Transfusion; 2011 May; 51(5):968-75. PubMed ID: 20880037
[TBL] [Abstract][Full Text] [Related]
15. Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: results of the prospective PREDICT trial.
Russell N; Douglas K; Ho AD; Mohty M; Carlson K; Ossenkoppele GJ; Milone G; Pareja MO; Shaheen D; Willemsen A; Whitaker N; Chabannon C
Haematologica; 2013 Feb; 98(2):172-8. PubMed ID: 22983579
[TBL] [Abstract][Full Text] [Related]
16. [Mobilization of peripheral blood stem cells with plerixafor in poor mobilizer patients].
Sancho JM; Duarte R; Medina L; Querol S; Marín P; Sureda A;
Med Clin (Barc); 2016 Sep; 147(5):223.e1-223.e7. PubMed ID: 27374031
[TBL] [Abstract][Full Text] [Related]
17. Incidence and risk factors of poor mobilization in adult autologous peripheral blood stem cell transplantation: a single-centre experience.
Lee KH; Jung SK; Kim SJ; Jang JH; Kim K; Kim WS; Jung CW; Kim DW; Kang ES
Vox Sang; 2014 Nov; 107(4):407-15. PubMed ID: 25130876
[TBL] [Abstract][Full Text] [Related]
18. Plerixafor plus pegfilgrastim is a safe, effective mobilization regimen for poor or adequate mobilizers of hematopoietic stem and progenitor cells: a phase I clinical trial.
Herbert KE; Demosthenous L; Wiesner G; Link E; Westerman DA; Came N; Ritchie DS; Harrison S; Seymour JF; Prince HM
Bone Marrow Transplant; 2014 Aug; 49(8):1056-62. PubMed ID: 24887382
[TBL] [Abstract][Full Text] [Related]
19. Plerixafor in patients with lymphoma and multiple myeloma: effectiveness in cases with very low circulating CD34+ cell levels and preemptive intervention vs remobilization.
Sánchez-Ortega I; Querol S; Encuentra M; Ortega S; Serra A; Sanchez-Villegas JM; Grifols JR; Pujol-Balaguer MM; Pujol-Bosch M; Martí JM; Garcia-Cerecedo T; Barba P; Sancho JM; Esquirol A; Sierra J; Duarte RF
Bone Marrow Transplant; 2015 Jan; 50(1):34-9. PubMed ID: 25222503
[TBL] [Abstract][Full Text] [Related]
20. Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient.
Stiff P; Micallef I; McCarthy P; Magalhaes-Silverman M; Weisdorf D; Territo M; Badel K; Calandra G
Biol Blood Marrow Transplant; 2009 Feb; 15(2):249-56. PubMed ID: 19167685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
